Indivior PLC $INDV Shares Sold by Geode Capital Management LLC

Geode Capital Management LLC cut its position in shares of Indivior PLC (NASDAQ:INDV) by 0.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 2,837,824 shares of the company’s stock after selling 18,607 shares during the quarter. Geode Capital Management LLC owned 2.27% of Indivior worth $101,840,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Salomon & Ludwin LLC acquired a new stake in Indivior in the 4th quarter valued at about $30,000. Harbor Capital Advisors Inc. lifted its holdings in Indivior by 309.9% in the 4th quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after acquiring an additional 781 shares during the last quarter. Quarry LP acquired a new stake in Indivior in the 3rd quarter valued at about $26,000. GAMMA Investing LLC lifted its holdings in Indivior by 544.6% in the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after acquiring an additional 1,013 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Indivior in the 2nd quarter valued at about $26,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Indivior Trading Up 0.5%

NASDAQ INDV opened at $37.62 on Friday. The stock’s 50-day moving average price is $34.61 and its two-hundred day moving average price is $34.10. The company has a market cap of $4.59 billion, a PE ratio of 19.29 and a beta of 0.88. Indivior PLC has a 1 year low of $13.42 and a 1 year high of $41.00.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $0.96 earnings per share (EPS) for the quarter. The firm had revenue of $317.00 million for the quarter. Indivior had a negative return on equity of 219.26% and a net margin of 19.44%. Research analysts forecast that Indivior PLC will post 4.05 EPS for the current fiscal year.

Analysts Set New Price Targets

INDV has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Indivior from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, Indivior currently has an average rating of “Buy” and an average price target of $39.33.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.